Introduction
============

The role of uric acid in the causation and progression of chronic kidney disease (CKD) has been debated; however, uric acid has been reconsidered as a potential contributory risk factor for the development and progression of CKD over the last 15 years ([@b1-etm-0-0-8694]). Excessive uric acid, usually in the form of monosodium urate (MSU) crystals, precipitates in synovial cavities and other anatomic location to induce severe inflammation and debilitating pain ([@b3-etm-0-0-8694]). In particular, deposits of uric acid in the kidney causes gouty nephropathy, which is the most serious complication of hyperuricemia ([@b3-etm-0-0-8694]). It is considered that the activation of renin-angiotensin, inflammatory factors, endothelial dysfunction and cyclooxygenase-2 (COX-2) serve important roles in gouty nephropathy ([@b5-etm-0-0-8694],[@b6-etm-0-0-8694]). The identified underlying mechanisms of gouty nephropathy have revealed that inflammation has a dominant role in its pathogenesis.

The Nod-like receptor protein 3 (NLRP~3~) inflammasome is comprised of NLRP~3~, apoptosis-associated speck like protein (ASC) and caspase-1 and is the most extensively studied inflammasome of recent years. It is involved in certain human inflammatory and autoimmune diseases, including cryopyrin-associated periodic syndrome, ischaemia reperfusion injury and atherosclerosis ([@b7-etm-0-0-8694],[@b8-etm-0-0-8694]). Following detection of cellular stress, NLRP~3~ oligomerizes by homotypic interactions between NACHT domains. The pyrin domains (PYD) of NLRP~3~ then becomes exposed for ASC binding. The caspase activation and recruitment domains (CARD) of ASC in turn recruits pro-caspase-1 through CARD-CARD interactions ([@b9-etm-0-0-8694]). Following NLRP~3~ inflammasome formation, procaspase-1 is converted to active caspase-1, which regulates the maturation of proinflammatory cytokines, including interleukin (IL)-1β and IL-18([@b10-etm-0-0-8694]), further aggravating renal damage.

MSU crystals cause the formation of inflammasomes *in vivo* ([@b11-etm-0-0-8694]). In addition, the inflammatory effect of MSU crystals is primarily mediated by NLRP~3~ inflammasomes driving the production of IL-1β and IL-18. IL-1β is likely the main agent that triggers systemic inflammation ([@b3-etm-0-0-8694]). Therefore, these observations prompted the present study to assess the role of the NLRP~3~ inflammasome in the mediation of the innate immune inflammatory response to MSU crystal deposition with regards to gouty nephropathy. The present study investigated the role of the NLRP~3~ inflammasome signalling pathway with the progression of hyperuricemia and gouty nephropathy, the results of which may provide a novel theoretical basis and therapeutic target for the early prevention and treatment of gouty nephropathy.

Materials and methods
=====================

### Study subjects

A total of 45 male patients (18-70 years old) were recruited at the People\'s Hospital of Shenzhen Baoan between July 2016 and December 2017. According to the inclusion and exclusion criteria, these patients were divided into three groups (n=15): The control group, the hyperuricaemia group and the gouty nephropathy group. The present study was approved by the Ethics Committee of the Affiliated Bao\'an Hospital of Shenzhen (approval no. BYL2016001). Written informed consent was obtained from all participants.

### Inclusion criteria

Patients in the control group received a health examination. There were no abnormalities in the laboratory indicators of the selected subjects and patients had no history of cardiovascular disease or liver disease (including diabetes and gout). Patients also had no presence of infection or autoimmune disease. Hyperuricaemia was defined as levels of serum uric acid \>6-7 mg/dl ([@b12-etm-0-0-8694]). The diagnosis of gouty nephropathy was based on the diagnosis of primary gout ([@b13-etm-0-0-8694]), with one or more of the following parameters: Urinary protein \>150 mg/dl; urine white blood cells \>5/high power field (HPF); urine red blood cells \>3/high power field; serum creatinine \>115 µmol/l; blood uric acid/creatinine ratio \>2.5; ultrasound or ureterography revealing renal calculus and kidney shrinkage. All of the aforementioned cases excluded urinary tract infections and other diseases such as cancer.

### Exclusion criteria

Exclusion criteria was based on previous literature ([@b14-etm-0-0-8694]) and was as follows: female; \<18 years old or \>70 years old; patients with secondary hyperuricaemia or stage 4-5 chronic kidney disease; acute hyperuricaemia and the presence of acute renal function deterioration factors; patients with severe cardiovascular disease, liver and kidney disease, lung disease, fractures, tumors, infectious and autoimmune disease, and mental illness; diseases that may affect NLRP~3~ inflammasome signalling pathways; patients who had been using uric acid drugs outside the hospital or had been treated with lipid-lowering drugs or anti-inflammatory and anti-oxidative drugs during the 4 weeks prior to admission.

### Detection of organ function indicators

Biochemical serum and urine samples were obtained following 8 h fasting. A total of 15 ml serum sample was collected from each patient and shipped to the Laboratory Services at the Affiliated Bao\'an Hospital of Shenzhen (Guangdong, China) for biochemical analysis, which was obtained by centrifugation at 500 x g for 10 min at 4˚C. Urinary biochemical parameters were measured from the patients\' first morning urine sample. Other standard parameters were measured including blood and urine analysis. The parameters tested for blood included white blood cell (WBC), red blood cell (RBC), hemoglobin (HB), platelets (PLT), total cholesterol (TC), total triglycerides (TG), low-density lipoprotein (LDL), high-density lipoprotein (HDL), total protein (TP), albumin (ALB), alanine aminotransferase (ALT), aspartate aminotransferase (AST), serum creatinine (Cr), uric acid (UC), blood urea nitrogen (BUN), prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT) and fibrinogen (FIB). Other parameters tested for urine were urine leukocytes, urine erythrocytes and urine protein.

### Isolation and culture of peripheral blood mononuclear cells

Centrifugation (speed, 1,600 x g; duration, 10 min; temperature, 4˚C) was performed on blood samples in an EDTA tube to obtain the buffy coat. Samples were stored at -80˚C for future use. Peripheral blood mononuclear cells were isolated with Ficoll-Paque Plus (GE Healthcare). Monocytes were isolated by magnetic bead negative selection according to the instructions of Dynabeads^®^ Untouched™ Human Monocytes kit (Invitrogen; Thermo Fisher Scientific, Inc.).

Isolated monocyte lysates were separated from which 5 µl was extracted for viability verification. Trypan Blue staining confirmed that the viability of the cells was \>95%. Cell concentration was then adjusted to 5x10^5^ cells/ml using a hemocytometer using the following formula: Number of cells/ml = number of cells counted in 100 small grids/100x400x10,000x dilution factor. The total number of monocytes was counted to be 34.311±19.912x10^5^. A third of which was used for RNA extraction, whilst the rest were used for western blotting. The number of monocytes for RNA extraction and western blot analysis were divided 1:2. A total of 200 µl TRIzol (Invitrogen; Thermo Fisher Scientific, Inc.) was added to monocytes for RNA extraction, whereas 30-50 µl PBS (Invitrogen; Thermo Fisher Scientific, Inc.) was added for western blotting experiments.

### Reverse transcription-quantitative PCR (RT-qPCR) to determine

NLRP3, ASC and caspase-1 mRNA expression in peripheral blood mononuclear cells. Total RNA was extracted from monocytes using TRIzol solution (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer\'s protocol. RNA concentration and purity were assessed via electrophoresis and a UV spectrophotometer (Thermo Fisher Scientific, Inc.), respectively. RNA was reverse transcribed to cDNA following the protocol provided by the RevertAid First Strand cDNA Synthesis kit (Thermo Fisher Scientific, Inc.). cDNA was stored at -20˚C prior to qPCR amplification using the TransStart^®^ Tip Green qPCR Supermix 2X kit (TransGen Biotech Co., Ltd.), using the SYBR-Green I fluorophore, according to manufacturer\'s protocol. All qPCR reactions were performed in an Applied Biosystems 7500 system (Applied Biosystems; Thermo Fisher Scientific, Inc.) using the following thermocycling conditions: Initial denaturation at 95˚C for 30 sec, followed by 40 cycles of 95˚C for 5 sec and 60˚C for 30 sec. Finally, the melting curve was generated (dissociation, 60˚C at 30 sec and 95˚C at 15 sec) to determine normality. Gene expression was calculated using the 2^-ΔΔCq^ method ([@b15-etm-0-0-8694]). β-actin was used as an internal reference for the mRNA levels of NLRP~3~, ASC and caspase-1 detected. The primer sequences used for qPCR are presented in [Table I](#tI-etm-0-0-8694){ref-type="table"}.

### Western blot analysis to determine

NLRP~3~, ASC and caspase-1 protein expression in peripheral blood mononuclear cells. Cells were lysed using ice-cold RIPA lysis buffer (Beijing Solarbio Science & Technology Co., Ltd.) and protein concentration was quantified using Bicinchoninic Acid Assay kit (Thermo Fisher Scientific, Inc.). Protein samples (10 µg) were separated by 8, 10 or 12% SDS-PAGE before being transferred to PVDF membranes. The membranes were then blocked with 5% milk dissolved in TBS supplemented with 1% Tween-20 at room temperature for 1 h, prior to incubation with primary antibodies against NLRP (1:300; cat. no. sc-134306; Santa Cruz Biotechnology, Inc.), caspase-1 (1:300; cat. no. sc-622; Santa Cruz Biotechnology, Inc.), ASC (1:300; cat. no. sc-514414; Santa Cruz Biotechnology, Inc.) or GAPDH (1:1,000; cat. no. A01020; Abbkine, Inc.) diluted in PBS supplemented with 0.1% Tween-20 (PBST) and 1% bovine serum albumin \[Sangon Biotech (Shanghai) Co., Ltd.\] at 4˚C overnight. Subsequently, the PVDF membranes were incubated with horseradish peroxidase-conjugated goat anti-mouse (1:1,000; cat.no. A0216; Beyotime Institute of Biotechnology) or goat anti-rabbit (1:10,000; cat. no. A21020-1; Abbkine, Inc.) secondary antibodies diluted in PBST supplemented with 5% milk at room temperature for 1 h with agitation. The proteins were then visualized using Pierce™ ECL Western Blotting Substrate (Thermo Fisher Scientific, Inc.) and all bands were analysed using Gel Doc™ XR+ Gel Documentation system (Bio-Rad Laboratories, Inc.) to calculate the densitometric values.

### ELISA for the determination of IL-1β and IL-18 levels in plasma

IL-1β (cat. no. 70-EK101B2) and IL-18 (cat. no. 70-EK1182) ELISA kits \[Hangzhou Multi Sciences (Lianke) Biotech Co., Ltd.\] were used to determine the concentration of IL-1β and IL-18 in 2 ml total plasma, according to manufacturer\'s protocol.

### Statistical analysis

Each experiment was repeated three times. All data were analysed using SPSS v.17.0 (SPSS, Inc.) software and expressed as the mean ± standard deviation. One-way analysis of variance was performed to compare the mean of multiple groups and a least significant difference post hoc test was used. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Kidney function is damaged in hyperuricaemia and gouty nephropathy groups

Patient general characteristics are provided in [Table II](#tII-etm-0-0-8694){ref-type="table"}, [Figs. 1](#f1-etm-0-0-8694){ref-type="fig"} and [2](#f2-etm-0-0-8694){ref-type="fig"}. The expression of uric acid ([Fig. 1C](#f1-etm-0-0-8694){ref-type="fig"}), blood urea nitrogen ([Fig. 1B](#f1-etm-0-0-8694){ref-type="fig"}) and blood lipids ([Fig. 1F](#f1-etm-0-0-8694){ref-type="fig"}) including total cholesterol, total triglycerides and low-density lipoprotein was higher in the hyperuricaemia and gouty nephropathy groups compared with the control group, but the level of high-density lipoprotein exhibited the opposite trend. Levels of urine leukocytes and erythrocytes were higher in the gouty nephropathy group compared with both the control and hyperuricemia groups (Fig. 2E-F). Serum creatinine ([Fig. 1A](#f1-etm-0-0-8694){ref-type="fig"}), uric acid ([Fig. 1C](#f1-etm-0-0-8694){ref-type="fig"}), blood urea nitrogen ([Fig. 1B](#f1-etm-0-0-8694){ref-type="fig"}) were greater in the gouty nephropathy group and hyperuricaemia group compared with the control group. Serum creatinine and urine protein are common indicators of renal function and used to monitor the progression of chronic kidney disease ([@b16-etm-0-0-8694]). These results demonstrated that the kidney had been further damaged in the progression from hyperuricaemia to gouty nephropathy.

### Successful peripheral blood mononuclear cell isolation

Peripheral blood mononuclear cells were isolated from the peripheral blood of 45 patients for *in vitro* experiments. Trypan blue staining ([Fig. 3](#f3-etm-0-0-8694){ref-type="fig"}) confirmed that \>95% were viable cells ([Table III](#tIII-etm-0-0-8694){ref-type="table"}).

### NLRP~3~, ASC and caspase-1 mRNA expression are increased in the hyperuricaemia and gouty nephropathy groups

NLRP~3~, ASC and caspase-1 mRNA levels were significantly increased in the hyperuricaemia and gouty nephropathy groups compared with the control group ([Table IV](#tIV-etm-0-0-8694){ref-type="table"}). Compared with the hyperuricaemia group, the gouty nephropathy group had a significantly higher expression of ASC and caspase-1 mRNA ([Table IV](#tIV-etm-0-0-8694){ref-type="table"}). The mRNA expression in peripheral blood mononuclear cells demonstrated that the NLRP~3~ inflammasome may serve a pivotal role in gouty nephropathy.

### Expression of NLRP~3~, ASC, caspase-1 protein increases in the hyperuricaemia and gouty nephropathy group

Gouty nephropathy group had a significantly higher expression of NLRP~3~, ASC and caspase-1 protein compared with the control group ([Table V](#tV-etm-0-0-8694){ref-type="table"}). The expression of ASC and caspase-1 protein was higher in the gouty nephropathy group compared with the hyperuricaemia group ([Table V](#tV-etm-0-0-8694){ref-type="table"}; [Fig. 4](#f4-etm-0-0-8694){ref-type="fig"}). Peripheral blood mononuclear cell protein expression ([Fig. 4](#f4-etm-0-0-8694){ref-type="fig"}; [Table V](#tV-etm-0-0-8694){ref-type="table"}) also corresponded with mRNA expression ([Table IV](#tIV-etm-0-0-8694){ref-type="table"}), indicating the important role of the NLRP~3~ inflammasome in gouty nephropathy.

### Expression of IL-1β and IL-18 is increased in the hyperuricaemia and gouty nephropathy group

IL-1β and IL-18 levels were significantly higher in the hyperuricaemia and gouty nephropathy groups compared with the control group ([Table VI](#tVI-etm-0-0-8694){ref-type="table"}). IL-1β expression was significantly elevated in the gouty nephropathy group compared with the hyperuricaemia group ([Table VI](#tVI-etm-0-0-8694){ref-type="table"}). The increased expression of inflammatory factors demonstrated that the NLRP~3~ inflammasome was associated with gouty nephropathy.

Discussion
==========

Uric acid is involved in the pathogenesis of kidney disease. Increasing evidence supports uric acid as a cause or exacerbating factor for kidney fibrosis and progressive CKD with an elevated serum uric acid level independently predicting the development of CKD ([@b17-etm-0-0-8694],[@b18-etm-0-0-8694]). Elevated uric acid levels induce oxidative stress and endothelial dysfunction, resulting in the development of both systemic and glomerular hypertension ([@b19-etm-0-0-8694],[@b20-etm-0-0-8694]). It is well established that uric acid forms urate crystals in sufficient concentrations to block renal collecting tubes, which causes interstitial nephritis, gouty nephropathy and interstitial fibrosis ([@b21-etm-0-0-8694]). Furthermore, the kidney damage caused by uric acid is the result of this sort of obstruction and crucially, it can be exacerbated by the inflammatory response that it initiates. Uric acid activates cytoplasmic phospholipase A2 and inflammatory transcription factor NF-κB, which increases the production of various systemic cytokines, including tumour necrosis factor-α, kidney monocyte chemotactic protein 1 and blood vessel COX-2 ([@b22-etm-0-0-8694],[@b23-etm-0-0-8694]). In addition, hyperuricaemia aggravates kidney injury by recruiting IL-1β-secreting macrophages, activating NLRP~3~ inflammasomes in macrophages and promoting chemokine secretion in proximal tubular cells ([@b24-etm-0-0-8694]). Uric acid, in its soluble form, is responsible for increasing the production of IL-1β in an NLRP~3~-dependent manner and is associated with kidney damage ([@b25-etm-0-0-8694]).

The inflammatory response is closely associated with the innate immune system. Intracellular nucleotide-binding oligomerization domain-like receptors form a group of pattern recognition receptors that are involved in a wide variety of innate host immune responses when stimulated by pathogen-associated molecular patterns dangerous-associated molecular patterns (DAMPs) ([@b26-etm-0-0-8694]). One of the most thoroughly investigated members is the intracellular pattern recognition receptor NLRP~3~ inflammasome complex consisting of NLRP~3~, ASC and caspase-1([@b27-etm-0-0-8694]). Upon activation, NLRP~3~ oligomerizes via homotypic interactions between NACHT domains and raises ASC and caspase to form an inflammatory complex, resulting in activated caspase-1. Activated caspase-1 cleaves intracellular IL-1β and IL-18 precursors to form mature IL-1β and IL-18, which are secreted into the extracellular matrix ([Fig. 5](#f5-etm-0-0-8694){ref-type="fig"}) ([@b28-etm-0-0-8694]). The inflammasome is understood to have a fundamental role in the progression of autoinflammatory diseases and to have additional roles in infection control, the progression of immune pathologies and the recognition of tissue damage. NLRP~3~ inflammasome is activated in response to a variety of infectious stimuli or by cellular stress caused by various sterile danger signals, including high concentrations of extracellular ATP, a decrease in extracellular osmolality or pH, crystals of MSU or cholesterol and the degradation of extracellular matrix components ([@b27-etm-0-0-8694]).

In the present study, the concentration of uric acid and creatinine as well as the expression of mRNA and protein in NLRP~3~ inflammasomes including NLRP~3~ mRNA, ASC mRNA, caspase-1 mRNA and ASC protein levels increased in the hyperuricaemia and gouty nephropathy groups compared with the control group. Importantly, the elevated levels of IL-1β and IL-18 indicated that NLRP~3~ inflammasomes were activated in hyperuricaemia and gouty nephropathy. The expression of ASC and caspase-1 mRNA and protein was higher in the gouty nephropathy group than in the hyperuricaemia group with the level of IL-1β also being significantly increased. The results indicated that the NLRP~3~ inflammasome was activated and induced the polymerization of the adaptor molecule ASC, leading to the production of IL-1β. Taken together, these results indirectly indicated that the NLRP~3~ inflammasome has a pivotal role in the progression of gouty nephropathy.

Although the specific activation mechanism of the NLRP~3~ inflammasome is unclear, recent studies have proposed three hypotheses regarding the activation of NLRP~3~ inflammasomes: Firstly, all bacteria, viruses, particles or crystals can stimulate cells to produce reactive oxygen species, which can activate the NLRP~3~ inflammasome ([@b29-etm-0-0-8694]). In the course of oxidative stress, thioredoxin, following its own oxidation, releases thioredoxin-interacting protein, activating the NLRP~3~ inflammasome ([@b30-etm-0-0-8694]). Secondly, crystals or particles, such as MSU, silicon dioxide, amyloid and cholesterol crystals, are phagocytosed by macrophages into lysosomes. This accumulation causes lysosomal rupture and the release of cathepsin B and other proteases, inducing the activation of the NLRP~3~ inflammasome ([@b31-etm-0-0-8694],[@b32-etm-0-0-8694]) Finally, stimulation induces cells to release ATP on the cell surface of the P2X7 purine receptor, triggering the potassium ion outflow mechanism and calcium wave transport mechanism leading to mitochondrial damage. This releases mitochondrial DNA (mtDNA) and activates the NLRP~3~ inflammasome ([@b33-etm-0-0-8694],[@b34-etm-0-0-8694]). Previous studies have demonstrated that NLRP~3~ can identify uric acid crystals and other dangerous signals ([@b3-etm-0-0-8694],[@b35-etm-0-0-8694]). Uric acid crystals trigger IL-1β-mediated inflammation by activating the NLRP~3~ inflammasome via the aforementioned three mechanisms ([@b36-etm-0-0-8694]).

The present study hypothesized that MSU acts as an endogenous DAMP, contributing to the progression of the NLRP~3~ inflammasome in hyperuricaemia and gouty nephropathy. When high levels of uric acid in the body cause uric acid crystals to be deposited in tissues, macrophages directly phagocytose urate crystals, which are too large to be efficiently cleared and are likely to induce the production of ROS on their way to becoming lysosomes ([@b9-etm-0-0-8694]). Following the phagocytosis of MSU, macrophages form phagocytic bodies and the subsequent intracellular rupture of these bodies releases cathepsin B, which activates the NLRP~3~ inflammasome ([@b37-etm-0-0-8694]). MSU also activates the NLRP~3~ inflammasome by causing intracellular potassium efflux ([@b38-etm-0-0-8694]), leading to mitochondrial damage. Furthermore, by releasing mtDNA, the maturation and release of IL-1β and IL-18 is stimulated. A previous study determined that uric acid activates NLRP~3~ inflammasomes via mitochondrial ROS production and their results demonstrated the direct role of hyperuricaemia in activating NLRP~3~ inflammasomes in macrophages ([@b39-etm-0-0-8694]). Berberine may influence the NLRP~3~ inflammasome and be involved in MSU crystal-induced innate immune responses, attenuating the expression of NLRP~3~, further inhibiting the downstream signalling of molecular IL-1β and eventually having a role in the treatment of gouty arthritis ([@b40-etm-0-0-8694]). The present study observed that gouty nephropathy is associated with elevated levels of uric acid in serum and high expression of NLRP~3~, ASC and caspase-1 mRNA and protein, as well as IL-1β and IL-18 expression. The present results indicated that uric acid-induced NLRP~3~ inflammasomes are associated with gouty nephropathy with the underlying mechanism potentially involving one of the aforementioned three hypotheses.

The present study has limitations as the exact association between NLRP~3~ inflammasomes and gouty nephropathy was not elucidated. Further studies are therefore required to explore the role of the NLRP~3~ inflammasome in humans and *in vivo*. In addition to the need for large clinical trials, more studies are required to better understand the biology of uric acid. To the best of our knowledge, clinical study into the regulation mechanism of the NLRP~3~ inflammasome signalling pathway with regards to gouty nephropathy has not been performed.

In conclusion, the present study demonstrated that the NLRP~3~ inflammasome was associated with the progression of hyperuricaemia and gouty nephropathy, leading to the inflammatory response and renal damage. Although the precise mechanism of the NLRP~3~ inflammasome signalling pathway and the means by which MSU triggers the inflammasome remains a matter of debate, the importance of the NLRP~3~ inflammasome in gouty nephropathy has been established. The present study proposes that future therapeutic strategies for gouty nephropathy should be based on blocking uric acid or inhibiting its activation of the NLRP~3~ inflammasome. Further studies will be required to explore the mechanism of how uric acid activates the NLRP~3~ inflammasome to allow for the early diagnosis of gouty nephropathy.
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![Organ function indicators of enrolled patients, including renal and liver function, coagulation and blood lipids. (A) Levels of Cr, (B) BUN, (C) UA, (D) coagulation functions, (E) liver function and (F) blood lipids of patients in the control, hyperuricemia and gouty nephropathy groups. ^\*^P\<0.05 and ^\*\*^P\<0.01, with comparisons indicated by lines. Cr, creatinine; BUN, blood urea nitrogen; UA, uric acid; PT, prothrombin time; APTT, activated partial thromboplastin time; TT, thrombin time; FIB, fibrinogen; TP, total protein; ALB, albumin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; TC, total cholesterol; TG, total triglycerides; HDL, high density lipoprotein; LDL, low density lipoprotein.](etm-20-01-0195-g00){#f1-etm-0-0-8694}

![Organ function indicators of enrolled patients, including blood and urine analysis. (A) WBC, (B) RBC, (C) HB, (D) PLT, (E) urine leukocytes and (F) urine erythrocytes levels of patients in the control, hyperuricemia and gouty nephropathy groups. ^\*^P\<0.05, with comparisons indicated by lines. WBC, white blood cell; RBC, red blood cell; HB, hemoglobin; PLT, platelets; HPF, high power field.](etm-20-01-0195-g01){#f2-etm-0-0-8694}

![Representative images of trypan blue staining of peripheral blood mononuclear cells (magnification, x10). Trypan Blue staining test was used to confirmed the cell viability, followed by the counting of cells. Trypan blue staining can stain dead cells blue, whilst the live cells are not colored. (A) Densely distributed colorless transparent particles under the microscope, representing live cells. (B) Scattered distribution of colorless transparent particles, showing fewer living cells. (C) Densely distributed colorless transparent particles, representing live cells. (D) Cell counting schematic. The area of every grid is 1.0 mm^2^ and the volume is 0.1 µl. Cells in the double-lined area were counted as red blood cells, whereas cells in the single-lined area counted as white blood cells. Magnification, x10.](etm-20-01-0195-g02){#f3-etm-0-0-8694}

![Expression of NLRP~3~, ASC and caspase-1 protein in peripheral blood mononuclear cells. Representative western blots of peripheral blood mononuclear cells isolated from control, hyperuricemia and gouty nephropathy patients. NLRP~3~, Nod-like receptor protein 3; ASC, apoptosis-associated speck like protein; C, control group; T, hyperuricemia group; S, gouty nephropathy group.](etm-20-01-0195-g03){#f4-etm-0-0-8694}

![Schematic demonstrating the activation of NLRP~3~ leading to release of proinflammatory factors. The NLRP~3~ inflammasome is comprised of NLRP~3~, ASC and caspase-1. When sensing danger signals, including PAMP and DAMP, NLRP~3~ oligomerizes via homotypic interactions between NACHT domains. The PYD of NLRP~3~ is then exposed for interaction with the PYD of ASC. The CARD of ASC in turn recruits pro-caspase-1 through CARD-CARD interactions, resulting in activated caspase-1. Activated caspase-1 then cleaves intracellular IL-1β and IL-18 precursors to form mature IL-1β and IL-18, which are secreted into the extracellular matrix. NLRP~3~, nucleotide-binding domain and leucine-rich repeat protein 3; ASC, apoptosis-associated speck like protein; LRR, leucine-rich repeat; NACHT, nucleotide-binding and oligomerization domain; PYD, pyrin domain; CARD, caspase recruitment domain; IL-1β, interleukin-1β; IL-18, interleukin-18; PAMP, pattern-associated molecular pattern; DAMP, danger-associated molecular pattern.](etm-20-01-0195-g04){#f5-etm-0-0-8694}

###### 

Primer sequences.

  Gene        Forward primer                      Reverse primer
  ----------- ----------------------------------- ----------------------------------
  β-actin     5\'-AACCGCGAGAAGATGACCCAGAT-3\'     5\'-GGATAGCACAGCCTGGATAGCA-3\'
  NLRP~3~     5\'-ATGGGTTTACTGGAGTACCTTTC-3\'     5\'-CTGTCTTCAATGCACTGGAATCTG-3\'
  ASC         5\'-GATGCTCTGTACGGGAAGGTC-3\'       5\'-TCCAGTTCCAGGCTGGTGT-3\'
  Caspase-1   5\'-GGAAGACTCATTGAACATATGCAAG-3\'   5\'-CTTGTCAAAGTCACTCTTTCAGTG-3\'

NLRP~3~, nucleotide-binding domain and leucine-rich repeat protein 3; ASC, apoptosis-associated speck like protein.

###### 

General characteristics of enrolled patients.

  Characteristics    Control (n=15)   Hyperuricemia (n=15)   Gouty nephropathy (n=15)
  ------------------ ---------------- ---------------------- --------------------------
  Age (years)        45.20±10.19      48.27±14.91            48.3±11.5
  Height (m)         1.72±0.06        1.70±0.05              1.66±0.05
  Body weight (kg)   72.25±6.97       69.98±12.08            61.39±6.83
  BMI (kg/m^2^)      24.28±1.53       24.38±4.53             22.19±2.43
  SBP (mmHg)         116.00±7.61      115.93±9.83            121.33±10.87
  DBP (mmHg)         79.27±7.98       76.47±7.60             74.80±8.78
  FBG (mmol/l)       4.73±0.45        5.17±0.70              4.77±0.39

Values are presented as the mean ± standard deviation. BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic pressure; FBG, fasting blood-glucose.

###### 

Peripheral blood mononuclear cells count.

  Group               n    Count (10^5^)
  ------------------- ---- ---------------
  Control             15   33.047±22.755
  Hyperuricemia       15   43.627±18.317
  Gouty nephropathy   15   26.567±13.506

###### 

Expression of NLRP~3~, ASC and caspase-1 mRNA in peripheral blood mononuclear cells.

  Group               n    NLRP~3~                                                    ASC                                                                                                     Caspase-1
  ------------------- ---- ---------------------------------------------------------- ------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------
  Control             15   23.54±1.19                                                 25.88±1.18                                                                                              26.99±1.43
  Hyperuricemia       15   26.05±1.89^[a](#tfn1-etm-0-0-8694){ref-type="table-fn"}^   27.49±3.56^[a](#tfn1-etm-0-0-8694){ref-type="table-fn"}^                                                28.05±2.41^[a](#tfn1-etm-0-0-8694){ref-type="table-fn"}^
  Gouty nephropathy   15   25.43±1.66^[a](#tfn1-etm-0-0-8694){ref-type="table-fn"}^   32.21±3.01^[a](#tfn1-etm-0-0-8694){ref-type="table-fn"},[c](#tfn3-etm-0-0-8694){ref-type="table-fn"}^   30.80±2.80^[a](#tfn1-etm-0-0-8694){ref-type="table-fn"},[b](#tfn2-etm-0-0-8694){ref-type="table-fn"}^

Values are presented as the mean ± standard deviation.

^a^P\<0.01 vs. the control group;

^b^P\<0.05 vs. the hyperuricemia group;

^c^P\<0.01 vs. the hyperuricemia group; NLRP~3~, nucleotide-binding domain and leucine-rich repeat protein 3; ASC, apoptosis-associated speck like protein.

###### 

Expression of NLRP~3~, ASC, caspase-1 protein in peripheral blood mononuclear cells.

  Group               n    NLRP~3~/GAPDH                                             ASC/GAPDH                                                                                              Caspase-1/GAPDH
  ------------------- ---- --------------------------------------------------------- ------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------
  Control             15   0.45±0.18                                                 0.22±0.08                                                                                              0.57±0.16
  Hyperuricemia       15   0.55±0.12                                                 0.26±0.11a                                                                                             0.57±0.16
  Gouty nephropathy   15   0.60±0.16^[b](#tfn5-etm-0-0-8694){ref-type="table-fn"}^   0.47±0.19^[a](#tfn4-etm-0-0-8694){ref-type="table-fn"},[c](#tfn6-etm-0-0-8694){ref-type="table-fn"}^   0.78±0.15^[b](#tfn5-etm-0-0-8694){ref-type="table-fn"},[c](#tfn6-etm-0-0-8694){ref-type="table-fn"}^

Values are presented as the mean ± standard deviation, GAPDH was used as an internal reference.

^a^P\<0.05 vs. the control group;

^b^P\<0.01 vs. the control group;

^c^P\<0.05 vs. the hyperuricemia group. NLRP3, nucleotide-binding domain and leucine-rich repeat protein 3; ASC, apoptosis-associated speck like protein.

###### 

Expression of IL-1β and IL-18 in plasma of patients.

  Group               n    IL-1β (pg/ml)                                                                                            IL-18 (pg/ml)
  ------------------- ---- -------------------------------------------------------------------------------------------------------- -------------------------------------------------------------
  Control             15   28.41±14.05                                                                                              323.35±96.16
  Hyperuricemia       15   55.19±16.79^[a](#tfn7-etm-0-0-8694){ref-type="table-fn"}^                                                718.16±211.42^[a](#tfn7-etm-0-0-8694){ref-type="table-fn"}^
  Gouty nephropathy   15   81.20±17.63^[a](#tfn7-etm-0-0-8694){ref-type="table-fn"},[b](#tfn8-etm-0-0-8694){ref-type="table-fn"}^   870.67±371.13^[a](#tfn7-etm-0-0-8694){ref-type="table-fn"}^

Values are mean ± standard deviation.

^a^P\<0.01 vs. control group;

^b^P\<0.01 vs. hyperuricemia group. IL-1β, interleukin-1β; IL-18, interleukin-18.
